FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,971,382 | -52.3% | 834,324 | -42.8% | 0.02% | -53.7% |
| Q1 2023 | $8,317,913 | +55.2% | 1,459,283 | +174.8% | 0.04% | +36.7% |
| Q4 2022 | $5,358,153 | -54.2% | 531,036 | +1.6% | 0.03% | -52.4% |
| Q3 2022 | $11,711,000 | -1.2% | 522,574 | +9.3% | 0.06% | +3.3% |
| Q2 2022 | $11,849,000 | +39.7% | 478,153 | +118.6% | 0.06% | +27.1% |
| Q1 2022 | $8,480,000 | -46.3% | 218,718 | -19.0% | 0.05% | -44.8% |
| Q4 2021 | $15,805,000 | +114.1% | 270,120 | +116.9% | 0.09% | +81.2% |
| Q3 2021 | $7,382,000 | +742.7% | 124,546 | +1133.3% | 0.05% | +700.0% |
| Q2 2021 | $876,000 | -72.6% | 10,099 | -71.3% | 0.01% | -77.8% |
| Q4 2020 | $3,202,000 | +186.4% | 35,218 | +25.9% | 0.03% | +200.0% |
| Q3 2020 | $1,118,000 | +47.3% | 27,965 | -18.1% | 0.01% | -59.1% |
| Q1 2020 | $759,000 | – | 34,166 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |